CereGate
Key Facts
| Invested since | 2019 |
| Based in | Hamburg |
About the company
CereGate is developing a Computer-Brain-Interface (“BCI”) platform that is already capable to successfully submit information into the human brain. The revolutionary software platform is clinically validated and allows for enhanced treatment of various neurological and psychiatric disorders. The CereGate platform is able to transmit information into the brain („Mind-Writing“), by utilizing state of the art neuromodulation technology. While focusing first on improving gait symptoms for Parkinson patients, CereGate aims to become a key enabling tech¬nology in the field of rehabilitation and (neuro)prosthetics.
Do you want to
know more about this company?
CereGate in the news
Zum Artikel
CereGate, the preeminent Computer-Brain-Interface Software Platform, advances in clinical development and secures financing from leading deep tech and mental health investors 468 Capital and re.Mind Capital
Zum Artikel
CereGate GmbH receives financing from High-Tech Gründerfonds to accelerate development of a new software platform for neuromodulation therapy
More startups from Life Sciences
In order to successfully treat the infected patient, you have to recognize and diagnose most reliably the infecting microbe. Noscendo changes the way infection causative microbes are identified. Through a …
To the complete profileof Noscendo
Exit
GME German Medical Engineering develops and markets a new generation of laser and lightsystems (small, light weight, modular) for the use in cosmetic and medical dermatology.
To the complete profileof GME
SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a …
To the complete profileof SRTD biotech
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain …
To the complete profileof Sedivention
Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in …
To the complete profileof Phialogics
Exit
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
To the complete profileof Emergence Therapeutics
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular …
To the complete profileof HepaRegeniX
Dimericon is a private biotech company focused on exploring the novel modality crosslinked helix dimers (Dimericons) to target hard-to-drug intracellular protein-protein interactions using rationally designed mimetics of helix dimers. The …
To the complete profileof Dimericon
Preventicus GmbH is developing smartphone-driven solutions to capture and analyze patients’ vital parameters for early preclinical risk screening of lifestyle-related illnesses. Seed funding for the Jena-based company is managed by …
To the complete profileof Preventicus
Hapila’s counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.
To the complete profileof HAPILA
Exit
GILUPI developed a nanostructured detector, which is temporarily inserted into the bloodstream. The aim is to spot specific blood cells in vivo and thus to detect diseases in a very …
To the complete profileof GILUPI
Hypros (formerly GWA Hygiene) offers innovative digital solutions for the healthcare sector. The focus is on relieving the burden on hospital staff and increasing patient safety. The company, which has …
To the complete profileof Hypros